Biolegend, 506508, PE anti-human IFN-γ Antibody, 50μg

Interferon-γ is a potent multifunctional cytokine which is secreted primarily by activated NK cells and T cells. Originally characterized based on anti-viral activities, IFN-γ also exerts anti-proliferative, immunoregulatory, and proinflammatory activities. IFN-γ can upregulate MHC class I and II antigen expression by antigen-presenting cells. The B27 antibody reacts with the human interferon-γ. The B27 antibody can neutralize the bioactivity of natural or recombinant IFN-γ.
50μg
Verified Reactivity: Human
Reported Reactivity: Chimpanzee, Baboon, Cynomolgus, Rhesus, African Green, Pigtailed Macaque, Sooty Mangabey
Antibody Type: Monoclonal
Host Species: Mouse
Immunogen: E. coli-expressed recombinant human IFN-γ
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)
Preparation: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application: ICFC - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.
Excitation Laser: Blue Laser (488 nm)Green Laser (532 nm)/Yellow-Green Laser (561 nm)
Application Notes: Flow Cytometry2: The fluorochrome-labeled B27 antibody is useful for intracellular immunofluorescent staining and flow cytometric analysis to identify IFN-? -producing cells within mixed cell populations. For intracellular cytokine staining protocol, please visit www.biolegend.com and click on the support section.Neutralization1,3,6,7: The Ultra-LEAF™ Purified antibody (Endotoxin <0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human IFN-? bioactivity (Cat. No. 506531).
Application References(PubMed link indicates BioLegend citation): Favre C, et al. 1989. Molec. Immunol. 26:17. (Neut) Kaur A, et al. 2002. J Virol. 76:3646. Abrams J, et al. 1992. Immunol. Rev. 127:5. (Neut) Andersson U, et al. 1999. Detection and quantification of gene expression. New York:Springer-Verlag. Rout N, et al. 2010. PLoS One 5:e9787. (FC) Acosta-Rodriguez EV, et al. 2007. Nat. Immunol. 9:942-9. (Neut) Gangur V, et al. 1998. FASEB J. 12:705-13. (Neut)
Product Citations: Rappazzo CG, et al. 2020. bioRxiv. . PubMed Loos C, et al. 2023. NPJ Vaccines. 8:34. PubMed Cheng MI, et al. 2023. Nat Immunol. 24:780. PubMed Adamo S, et al. 2023. Cell Host Microbe. 31:928. PubMed Mo Y, et al. 2022. Front Immunol. 12:799896. PubMed Vorkas CK, et al. 2022. J Immunol. 208:1042. PubMed Hong Y, et al. 2022. J Leukoc Biol. 112:425. PubMed Li Y, et al. 2022. J Oncol. 2022:4544773. PubMed Bates TA, et al. 2022. Cell Rep. 41:111544. PubMed Sano Y, et al. 2023. Anticancer Res. 43:547. PubMed Pušnik J, et al. 2023. Nat Commun. 14:572. PubMed Khojandi N, et al. 2021. Cancer Immunol Res. 9:214. PubMed Ali A, et al. 2020. J Infect Dis. 222:853. PubMed Roberts A, et al. 2021. Sci Rep. 11:4030. PubMed Bilich T, et al. 2021. Cancer Discov. 11:1982. PubMed Xun X, et al. 2021. Am J Transl Res. 13:4360. PubMed Peng Q, et al. 2022. EBioMedicine. 77:103904. PubMed Lübke M, et al. 2020. J Exp Med. 217:00:00. PubMed Bauer J, et al. 2022. Nat Commun. 13:6401. PubMed Das J, et al. 2021. Med (N Y). 2:1269. PubMed Bilich T, et al. 2021. Science Translational Medicine. 13(590):. PubMed Qiu C, et al. 2022. Front Immunol. 12:764949. PubMed Rice TF, et al. 2021. EBioMedicine. 72:103612. PubMed Heitmann JS, et al. 2021. Nature. Online ahead of print. PubMed Minassian AM, et al. 2021. Med (N Y). 2:701. PubMed Punik J, et al. 2021. Cell Reports. 35(13):109320. PubMed Such L, et al. 2020. J Clin Invest. 4266:130. PubMed Ni J, et al. 2020. Immunity. 52(6):1075-1087.e8. PubMed Grace PS, et al. 2021. Front Immunol. 12:679973. PubMed Imura Y, et al. 2020. JCI Insight. :5. PubMed Xu C, et al. 2020. Methods Mol Biol. 2108:159. PubMed Duque JSR, et al. 2022. Nat Commun. 13:3700. PubMed Reuschl AK, et al. 2022. Cell Rep. 39:110650. PubMed Atyeo C, et al. 2022. Nat Commun. 13:3571. PubMed Crump NT, et al. 2021. Cell Reports. 35(6):109101. PubMed Zhong M, et al. 2022. Cell Death Dis. 13:671. PubMed Niu M, et al. 2021. Cell Reports. 36(8):109611. PubMed Luo Z, et al. 2021. Int J Mol Sci. 22:. PubMed Jeong HO, et al. 2022. iScience. 25:105358. PubMed Li L, et al. 2022. JCI Insight. 7:. PubMed Cimen Bozkus C, et al. 2021. STAR Protoc. 2:100758. PubMed
RRID: AB_315439 (BioLegend Cat. No. 506506) AB_315440 (BioLegend Cat. No. 506507)
Structure: Cytokine; dimer; 20-25 kD (Mammalian)
Bioactivity: Antiviral/antiparasitic activities; inhibits proliferation; enhances MHC class I and II expression on APC
Cell Sources: CD8+ and CD4+ T cells, NK cells
Cell Targets: T cells, B cells, macrophages, NK cells, endothelial cells, fibroblasts
Receptors: IFN-γRα (CDw119) dimerized with IFN-γRβ (AF-1)
Cell Type: Tregs
Biology Area: Cell Biology, Immunology, Neuroinflammation, Neuroscience
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. De Maeyer E, et al. 1992. Curr. Opin. Immunol. 4:321. 3. Farrar M, et al. 1993. Annu. Rev. Immunol. 11:571. 4. Gray P, et al. 1987. Lymphokines 13:151.
Regulation: Upregulated by IL-2, FGF-basic, EGF; downregulated by vitamin D3 or DMN; labile at pH2
Gene ID: 3458
UniProt: View information about IFN-gamma on UniProt.org
Clone: B27
Regulatory Status: RUO
Other Names: Interferon-γ, Immune interferon, Type II interferon, T cell interferon, Macrophage-activating factor (MAF), IFN-g, IFN-gamma
Isotype: Mouse IgG1, κ
Q: What type of PE do you use in your conjugates?
A: We use R-PE in our conjugates.